Provided by Tiger Fintech (Singapore) Pte. Ltd.

FibroGen

8.69
-0.3800-4.19%
Post-market: 9.100.4100+4.72%18:48 EST
Volume:44.17K
Turnover:391.30K
Market Cap:35.15M
PE:0.16
High:9.16
Open:9.06
Low:8.60
Close:9.07
52wk High:21.94
52wk Low:4.85
Shares:4.05M
Float Shares:3.62M
Volume Ratio:0.63
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):53.38
EPS(LYR):-11.8895
ROE:-1015.79%
ROA:-11.85%
PB:-2.06
PE(LYR):-0.73

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)

TIPRANKS
·
Nov 11

FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties

TIPRANKS
·
Nov 11

FibroGen’s Strategic Moves and Financial Highlights

TIPRANKS
·
Nov 11

FibroGen reports Q3 EPS ($3.25), consensus ($4.01)

TIPRANKS
·
Nov 11

FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate

Benzinga
·
Nov 11

FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

Reuters
·
Nov 11

FibroGen Inc: Q3 EPS $49.61

THOMSON REUTERS
·
Nov 11

FibroGen Inc expected to post a loss of $4.00 a share - Earnings Preview

Reuters
·
Nov 08

BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing

Reuters
·
Nov 07

FibroGen Receives $6.4 Million Payment from AstraZeneca

TIPRANKS
·
Nov 07

FibroGen Receives $6.4 Million Payment From AstraZeneca Following China Operations Sale

Reuters
·
Nov 07

BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy

Reuters
·
Sep 25

William Blair Remains a Hold on FibroGen (FGEN)

TIPRANKS
·
Sep 24

FibroGen Price Target Maintained With a $43.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 24

FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat

TIPRANKS
·
Sep 24

BRIEF-FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Reuters
·
Sep 24

FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker

Reuters
·
Sep 24

FibroGen Inc - Interim Analysis of Trial Expected in 2H 2026

THOMSON REUTERS
·
Sep 24

FibroGen Inc - Topline Results of FG-3246 in Combination With Enzalutamide in Patients With Mcrpc Enzalutamide Expected Q4 2025

THOMSON REUTERS
·
Sep 24

FGEN Enhances Share Capital Management with Treasury Share Purchase

TIPRANKS
·
Sep 23